- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03758131
Peer MI in FQHCs for Substance-using Emerging Adults
Peer-enhanced Motivational Interviewing in Federally-Qualified Health Clinics for Substance-using Emerging Adults
Studie Overzicht
Toestand
Gedetailleerde beschrijving
This project randomizes peer dyads, consisting of one Emerging Adult (EA), 18-29 years old, who both has a substance use problem and attends a Federally-qualified Health Center (i.e. target client), and one peer, to one of three conditions. In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change. With the "peer" of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use. In the Motivational Interviewing only (MI) condition, the target client alone will receive the MI intervention with no peer participation. In the Waitlist (WC) condition, target clients and peers can receive the intervention at 2 months into the follow-up period for the PMI group.
The main purpose of this study is to test whether a Peer-Enhanced Motivational Interviewing (PMI) intervention, which has been successful with college students, results in superior alcohol and marijuana use outcomes for emerging adults (EA), ages 18-29, who are clients of Federally-qualified Health Centers, and their peers. Seventy-five peer dyads (total n = 150, ntarget client = 75, npeer = 75) will be randomized to receive either Peer-Enhanced Motivational Interviewing (PMI), Motivational Interviewing only (MI) or Waitlist Control (WC.)
Studietype
Inschrijving (Verwacht)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Douglas C Smith, PhD
- Telefoonnummer: 217-333-5308
- E-mail: smithdc@illinois.edu
Studie Contact Back-up
- Naam: Maggie A Helms, MBA
- Telefoonnummer: 217-300-1159
- E-mail: mhlms@illinois.edu
Studie Locaties
-
-
Illinois
-
Urbana, Illinois, Verenigde Staten, 61801
- School of Social Work
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
For the Target Client
- Score 5 or higher on the AUDIT-C measure and/or use alcohol or marijuana 13 days or more out of the past 90 days,
- Have a friend that they are willing to refer to the study to be their 'peer' (support) and that peer agrees to participate,
- Are able to complete baseline and follow-up assessments and have a valid email,
- Are willing to be video recorded, and
- Are fluent in English
For the Peer
- Have weekly contact with the participating Target Client who referred them,
- Are will to attend all study procedures (i.e. baseline assessment, intervention, follow up),
- Are willing to be video record,
- Are fluent in English
Exclusion Criteria:
For the Target Client
- Are current students in the lead Investigator's classes,
- Are seeking residential treatment at the time of the screening call,
- Are incarcerated or court-ordered to receive treatment at the time of the screening call,
- Use drugs besides marijuana or alcohol over 45 of the past 90 days.
For the Peer
- Are current students in the lead Investigator's classes,
- Are seeking residential treatment at the time of the screening call,
- Are incarcerated or court-ordered to receive treatment at the time of the screening call,
- Use drugs besides marijuana or alcohol over 45 of the past 90 days,
- Are romantic partners of the Target Client
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Peer-enhanced Motivational Interviewing
In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use.
Mi is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change.
With the "peer" of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use.
|
In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use.
MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change.
With the "peer" of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use.
Andere namen:
|
|
Actieve vergelijker: Motivational Interviewing
In the Motivational Interviewing (MI) condition, target clients only will receive one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use.
|
In the Motivational Interviewing (PMI) condition, target clients only will receive one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use.
MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change.
Andere namen:
|
|
Placebo-vergelijker: Waitlist Control
Those dyads randomized to the Waitlist Control (WC) condition willl be offered teh PMI intervention at month 2 post-intervention for the PMI arm.
|
In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use.
MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change.
With the "peer" of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use.
Andere namen:
Dyads randomized to this intervention will have no contact with study personnel until 2 months after the PMI group has completed the PMI intervention.
Then those in the Waitlist Control condition will receive the full PMI protocol.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change: Global Appraisal of Individual Needs (GAIN) Substance Problem Scale
Tijdsspanne: Baseline and at month 1, 2, 3, 6 and 9 post-intervention period
|
A 16-item scale composed of lifetime symptoms of substance abuse, dependence, and substance-induced health and psychological disorders based on the Diagnostic and Statistical Manual of Mental Disorders (DSM) -IV.
|
Baseline and at month 1, 2, 3, 6 and 9 post-intervention period
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change: Marijuana Consequences Questionnaire (MACQ)
Tijdsspanne: Baseline and at month 1, 2, 3, 6 and 9 post-intervention period
|
A 50-item self-report measure modeled after the Young Adult Alcohol Consequences Questionnaire (YAACQ) assessing marijuana problems over the past 6 months.
A 6-month time frame was chosen to adequately capture potential infrequent consequences among marijuana users.
Each item is rated dichotomously (yes/no) to indicate whether the marijuana-related problem occurred in the last 6 months.
|
Baseline and at month 1, 2, 3, 6 and 9 post-intervention period
|
|
Change: Days of Combined Cannabis and Alcohol Use
Tijdsspanne: Baseline and at month 1, 2, 3, 6 and 9 post-intervention period
|
Past month measure of days (out of past 30) when participant used both marijuana and alcohol (based on Stein et al., 2018)
|
Baseline and at month 1, 2, 3, 6 and 9 post-intervention period
|
|
Change: Days of Cannabis and Binge Alcohol Use
Tijdsspanne: Baseline and at month 1, 2, 3, 6 and 9 post-intervention period
|
Past month measure of days (out of past 30) of use of either substance.
Binge drinking calculated from Time-Line Follow-Back (TLFB) as number of days of consuming 4+ (females)/5+ (males) drinks.
Items drawn from GAIN's Substance Frequency Scale.
|
Baseline and at month 1, 2, 3, 6 and 9 post-intervention period
|
|
Change: Drinking Consequences
Tijdsspanne: Baseline and at month 1, 2, 3, 6 and 9 post-intervention period
|
From the Rutgers Alcohol Problems Index and used to indicate indicates the frequency of experiencing negative consequences due to alcohol use.
|
Baseline and at month 1, 2, 3, 6 and 9 post-intervention period
|
|
Change: Urine Testing
Tijdsspanne: Baseline and at month 1, 2, 3, 6 and 9 post-intervention period
|
National Institute of Drub Abuse-approved urine test kit to determine presence of Marijuana metabolites in urine.
|
Baseline and at month 1, 2, 3, 6 and 9 post-intervention period
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Douglas C Smith, PhD, University of Illinois Urbana Champaign School of Social Work
Studie record data
Bestudeer belangrijke data
Studie start (Verwacht)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- Smith17393FQHC
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Stoornissen in het gebruik van middelen
-
University of HoustonOnbekend
-
UCB Biopharma SRLNog niet aan het wervenOntwikkelings- en epileptische encefalopathieën | SLC6A1 Neurodevelopmental Disorder (NDD)
-
New York City Health and Hospitals CorporationBeëindigdGlaucoom | Ziekte van het netvlies | Visuele Pathway DisorderVerenigde Staten
-
Egas Moniz - Cooperativa de Ensino Superior, CRLWervingVerlangen | Verslaving aan sociale media | Internet verslaving | Craving to Use Social MediaPortugal
-
Neuro-Eye Diagnostic Systems, LLCNeuro-ophthalmology of Texas PLLCAanmelden op uitnodigingMacula ziekte | Visuele Pathway Disorder | Ziekte van de oogzenuwVerenigde Staten
-
Otsuka Pharmaceutical Co., Ltd.WervingAttention-deficit Hyperactivity Disorder (ADHD)Japan
-
Assistance Publique - Hôpitaux de ParisNog niet aan het wervenMajor Depressive Disorder (MDD) met slapeloosheidFrankrijk
-
Otsuka Pharmaceutical Co., Ltd.WervingAttention-deficit Hyperactivity Disorder (ADHD)Japan
-
Fondazione G.B. Bietti, IRCCSVoltooidGlaucoom | Optische neuropathie, ischemische | Optische zenuw | Visuele Pathway Disorder | Neurale geleidingItalië
-
University of MiamiNational Eye Institute (NEI)VoltooidGlaucoom | Maculaire degeneratie | Retinale degeneratie | Optische neuropathie | DrDeramus verdachte | Visuele Pathway DisorderVerenigde Staten
Klinische onderzoeken op Peer-enhanced Motivational Interviewing
-
Air Liquide Healthcare SpainVoltooid
-
Boston Children's HospitalNational Institute on Drug Abuse (NIDA)Aanmelden op uitnodigingCannabisgebruiksstoornisVerenigde Staten
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI); East Carolina UniversityVoltooidColorectale kankerVerenigde Staten
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)Actief, niet wervendStoppen met rokenVerenigde Staten
-
Memorial Sloan Kettering Cancer CenterVoltooidSchildklierkanker | Papillair microcarcinoomVerenigde Staten